NASDAQ:CDLX - Cardlytics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.35 -0.78 (-4.84 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$15.35
Today's Range$15.10 - $16.09
52-Week Range$9.80 - $28.29
Volume151,927 shs
Average Volume218,996 shs
Market Capitalization$310.99 million
P/E Ratio-7.17
Dividend YieldN/A
BetaN/A
Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
SectorBusiness Services
Current SymbolNASDAQ:CDLX
CUSIPN/A
Phone888-798-5802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150.68 million
Book Value$2.56 per share

Profitability

Net Income$-53,040,000.00

Miscellaneous

EmployeesN/A
Market Cap$310.99 million
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

How were Cardlytics' earnings last quarter?

Cardlytics Inc (NASDAQ:CDLX) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.37. Cardlytics had a negative return on equity of 92.07% and a negative net margin of 35.20%. View Cardlytics' Earnings History.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Cardlytics.

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics issued an update on its first quarter 2019 earnings guidance on Tuesday, March, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $34.5-36.5 million, compared to the consensus revenue estimate of $41.79 million.

What price target have analysts set for CDLX?

7 brokerages have issued 12-month price targets for Cardlytics' stock. Their predictions range from $15.00 to $28.00. On average, they expect Cardlytics' stock price to reach $23.1667 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price. View Analyst Price Targets for Cardlytics.

What is the consensus analysts' recommendation for Cardlytics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardlytics.

What are Wall Street analysts saying about Cardlytics stock?

Here are some recent quotes from research analysts about Cardlytics stock:
  • 1. According to Zacks Investment Research, "Cardlytics, Inc. is engaged in developing a purchase intelligence platform. The purchase data includes debit, credit and bill pay data from online and in-store transactions. It helps the marketers identify, reach and influence likely buyers at scale, and measure the impact of marketing spends. The Company also operates an advertising channel, Cardlytics Direct. Cardlytics Direct delivers tailored marketing for marketers and financial institutions. Cardlytics, Inc. is based in ATLANTA, United States. " (3/20/2019)
  • 2. SunTrust Banks, Inc. analysts commented, "We maintain a Buy rating and adjust our price target to $25 (from $27) as Cardlytics processes the large amount of new users and works to build advertiser demand to fill the rapidly growing inventory from the higher MAUs. 4Q18 financial results were better than expected as the JPM launch increased users by 42% but 1Q guidance was weaker than expected as revenues came in light as CDLX focused on ensuring a successful JPM launch that would build the foundation for future revenue growth. Our thesis remains intact and we believe CDLX is attractive at 2.1x EV/Revenues on our FY19 estimates. CDLX Reports Solid 4Q18 Results. Cardlytics reported higher than expected results as revenues and adj. EBITDA were $47.8M and $0.3M versus consensus expectations of $46.4M and ($1.4M), respectively." (3/6/2019)

Has Cardlytics been receiving favorable news coverage?

Media coverage about CDLX stock has trended neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cardlytics earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near future.

Who are some of Cardlytics' key competitors?

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Range Resources (RRC), Caterpillar (CAT), Alibaba Group (BABA), Cloudera (CLDR), Ford Motor (F), First Data (FDC), Array Biopharma (ARRY), Paratek Pharmaceuticals (PRTK), Ferrari (RACE) and Nutanix (NTNX).

Who are Cardlytics' key executives?

Cardlytics' management team includes the folowing people:
  • Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)
  • Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)
  • Mr. David Evans, CFO & Head of Corp. Devel.
  • Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)
  • Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54)

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.85%), Canaan Partners VIII LLC (11.69%), Frontier Capital Management Co. LLC (7.22%), Jennison Associates LLC (6.24%), Cannell Capital LLC (2.50%) and BlackRock Inc. (2.09%). Company insiders that own Cardlytics stock include David Thomas Evans, Kirk Somers, Lynne Marie Laube, Polaris Venture Management Co and Scott D Grimes. View Institutional Ownership Trends for Cardlytics.

Which institutional investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Northern Trust Corp and Kornitzer Capital Management Inc. KS. Company insiders that have sold Cardlytics company stock in the last year include David Thomas Evans, Kirk Somers, Lynne Marie Laube, Polaris Venture Management Co and Scott D Grimes. View Insider Buying and Selling for Cardlytics.

Which institutional investors are buying Cardlytics stock?

CDLX stock was purchased by a variety of institutional investors in the last quarter, including Canaan Partners VIII LLC, Frontier Capital Management Co. LLC, Cannell Capital LLC, Jennison Associates LLC, Penn Capital Management Co. Inc., UBS Oconnor LLC, UBS Oconnor LLC and Edmond DE Rothschild Holding S.A.. Company insiders that have bought Cardlytics stock in the last two years include David Thomas Evans and Scott D Grimes. View Insider Buying and Selling for Cardlytics.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $15.35.

How big of a company is Cardlytics?

Cardlytics has a market capitalization of $310.99 million and generates $150.68 million in revenue each year. The company earns $-53,040,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

What is Cardlytics' official website?

The official website for Cardlytics is http://www.cardlytics.com.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]


MarketBeat Community Rating for Cardlytics (NASDAQ CDLX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote "Outperform" if you believe CDLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel